Drug Trial Radar · NCT04835584
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: Mar 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
109
Planned (sponsor's estimate)
Start
May 7, 2021
Primary completion
Dec 31, 2024
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Kartos Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Conditions
- Chronic Myeloid Leukemia
Interventions
KRT-232Drug
KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
DasatinibDrug
Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
NilotinibDrug
Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Maximum tolerated dose (MTD)/maximum administered dose (MAD) of KRT-232Time frame: 28 Days
- Part 2, Arm A and B: Major molecular response (MMR) rateTime frame: 6 months
- Part 2, Arm C: Major hematological response (MaHR) rateTime frame: 6 months
Locations
26 sites in 8 countries. Site status is shown where the registry gives one.
University of Alabama Birmingham
Birmingham, Alabama · Recruiting
Georgia Cancer Center at Augusta University
Augusta, Georgia · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
Texas Oncology- Sammons CC at Baylor
Dallas, Texas · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Princess Margaret Cancer Center
Toronto, Ontario, Canada · Recruiting
Centre Leon Berard
Lyon, France · Recruiting
APHM Hopital de la Timone
Marseille, France · Recruiting
Institut Paoli-Calmettes
Marseille, France · Recruiting
Centre Hospitalier Lyon Sud
Saint-Genis-Laval, France · Recruiting
Azienda Ospedaliero - Universitaria Mater Domini
Catanzaro, Italy · Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
Meldola FC, Italy · Recruiting
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy · Recruiting
Policlinico di Milano Ospedale Maggiore | Fondazione IRCCS Ca' Granda
Milan, MI, Italy · Recruiting
Pratia Onkologia Katowice
Katowice, Poland · Recruiting
National Medical Research Center of Hematology
Moscow, Russia · Recruiting
Almazov National Medical Research Center
Saint Petersburg, Russia · Recruiting
Samara State Medical University
Samara, Russia · Recruiting
Kyungpook National University Hospital
Daegu, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital
Seoul, South Korea · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Clínica Universidad de Navarra
Madrid, Navarre, Spain · Recruiting
Clinica Universidad de Navarra
Pamplona, Navarre, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.